|1.||Baguley, Bruce C: 27 articles (01/2014 - 01/2002)|
|2.||Ching, Lai-Ming: 21 articles (03/2014 - 01/2002)|
|3.||Kestell, Philip: 17 articles (06/2009 - 01/2002)|
|4.||Paxton, James W: 12 articles (06/2009 - 01/2002)|
|5.||Baguley, B C: 10 articles (04/2007 - 01/2000)|
|6.||Zhou, Shufeng: 10 articles (04/2005 - 01/2002)|
|7.||Seshadri, Mukund: 9 articles (02/2012 - 06/2005)|
|8.||McKeage, Mark J: 9 articles (08/2011 - 03/2006)|
|9.||Wang, Liang-Chuan S: 8 articles (11/2011 - 03/2004)|
|10.||Horsman, Michael R: 6 articles (01/2014 - 05/2002)|
07/15/2007 - "Although classified as a "vascular disrupting agent," we have recently conducted studies showing that DMXAA has remarkable efficacy in a range of tumors, working primarily as an immune modulator that activates tumor-associated macrophages and induces a subsequent CD8(+) T-cell-mediated response. "
12/15/2005 - "DMXAA treatment was highly effective in both small and large flank tumors. "
07/01/2006 - "These results indicate that DMXAA may be clinically beneficial in the management of head and neck cancers, alone or in combination with other treatments."
12/15/2005 - "Animals cured of tumors by DMXAA generated a systemic memory response and were resistant to tumor cell rechallenge. "
06/01/2003 - "Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid."
08/01/2009 - "Contrast-enhanced magnetic resonance imaging (MRI) and diffusion-weighted MRI were used to characterize the vascular and cellular responses of GL261 and U87 gliomas to DMXAA treatment. "
03/01/2014 - "Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma."
08/01/2009 - "In this study, we examined the in vivo efficacy of the tumor-VDA 5,6-dimethylxanthenone-4-acetic acid (DMXAA) against gliomas. "
01/01/1994 - "Treatment with LPS did not induce a significant delay in growth, despite extensive tumour haemorrhagic necrosis, whereas with 5,6-MeXAA, treatments that improved the cure rate did not necessarily give longer growth delays. "
08/12/2002 - "The results suggest an important role for tumour necrosis factor in mediating both the host toxicity and antitumour activity of 5,6-dimethylxanthenone-4-acetic acid, but also suggest that tumour necrosis factor can be replaced by other vasoactive factors in its antitumour action, an observation of relevance to current clinical studies."
03/01/2014 - "Concentrations of DMXAA in plasma and brain were measured by LC-MS/MS. DMXAA (25 mg/kg) caused widespread necrosis at 24 h, a 9-day growth delay and complete regressions in 50 % of the mice with subcutaneous GL261 tumours. "
03/01/2008 - "DMXAA induces tumour necrosis factor (TNF) in mice and the effects on vascular permeability are hypothesised to result from both direct (DMXAA) and indirect (TNF) effects. "
04/01/2007 - "Four of five DMXAA-treated animals showed necrosis involving 3.7-41.2% of the area of the tumour section at 24 h compared with none of four control animals (P < 0.028, Chi-square test). "
|4.||Lung Neoplasms (Lung Cancer)
04/02/2013 - "In several different murine models of immunotherapy for lung cancer, DMXAA-induced macrophage activation significantly augmented the therapeutic effects of immunotherapy. "
12/15/2005 - "The goal of this study was to carefully define the immune effects of DMXAA in a series of murine lung cancer and mesothelioma cell lines with varying immunologic characteristics. "
12/15/2005 - "Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma."
04/15/2010 - "In clinical trials, compared with chemotherapy alone, ASA404 was tolerated well and produced improved activity in patients with nonsmall cell lung cancer when combined with paclitaxel and carboplatin. "
03/01/2008 - "One such VDA, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), is scheduled for phase III trials for prostate and lung cancer in combination with conventional chemotherapies. "
07/30/2015 - "A study employing TLC/MALDI-MS and MALDI-MS imaging to examine LS174T colorectal adenocarcinoma xenografts following administration of DMXAA has been conducted into this effect. "
07/30/2015 - "LS174T colorectal adenocarcinoma xenografts grown in male immune-deficient mice were treated with 27.5 mg/kg DMXAA. "
03/01/2008 - "In mice bearing Lewis lung adenocarcinomas, a single intraperitoneal dose of DMXAA was shown to effect a highly significant reduction in tumor growth rate in wild-type mice that was not seen in IFN-beta-null mice. "
01/01/2014 - "The DMXAA responses of primary adenocarcinomas in K-rasLA1/+ transgenic mice, as well as syngeneic subcutaneous and metastatic tumors, generated by a p53R172HΔg/+; K-rasLA1/+ NSCLC line (344SQ-ELuc), were assessed both by in vivo bioluminescence imaging as well as by histopathology. "
08/01/1998 - "We show here that thalidomide (100 mg kg(-1)) has no effect when administered with inactive doses of DMXAA, and that it must be given simultaneously with an active dose of DMXAA to have its maximum potentiating effect on the growth of the murine Colon 38 adenocarcinoma. "
|4.||Acetic Acid (Vinegar)
|8.||combretastatin A-4 (combretastatin A4)
|9.||flavone acetic acid
|10.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)